BTIG Reiterates Buy Rating on Enliven Therapeutics (ELVN)

BTIG analyst Justin Zelin reiterated a Buy rating and $45.00 price target on Enliven Therapeutics (NASDAQ: ELVN).

The analyst comments "We continue to see ELVN-001 as a well-designed, next gen TKI showing differentiated efficacy and safety in the $9B TAM for CML. The latest EHA data for ELVN-001 continues to show an impressive 24 wk MMR at 47% among all pts and a notable 35% MMR among prior asciminib/ponatinib treated pts. Safety continued to look clean with low rates of heme AEs, discontinuations due to AEs, as well as dose reductions or interruptions. ELVN aims to start a ph 3 pivotal trial in the 2L+ or 3L+ setting in 2026. With the June raise, the co now has cash runway into 1H29 and through pivotal readouts for ELVN-001. Reiterate our Buy rating and $45 PT."

For an analyst ratings summary and ratings history on Enliven Therapeutics click here. For more ratings news on Enliven Therapeutics click here.

Shares of Enliven Therapeutics closed at $19.99 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Home Depot (HD) call put ratio 1.5 calls to 1 put with a focus on September 330 puts into quarter results
• Aurora Spine settles patent dispute, secures $600K insider loan